How to use liquid biopsies to treat patients with cancer

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

(2020) Matthew D. Hellmann et al.   CLINICAL CANCER RESEARCH

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors

(2020) Christopher G. Smith et al.   Genome Medicine

Integrating genomic features for non-invasive early lung cancer detection

(2020) Jacob J. Chabon et al.   NATURE

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

(2020) M.C. Liu et al.   ANNALS OF ONCOLOGY

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group

(2020) L. De Mattos-Arruda et al.   ANNALS OF ONCOLOGY

Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis

(2020) Hyo Jung Park et al.   RADIOLOGY

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

(2020) Nicholas C Turner et al.   LANCET ONCOLOGY

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

(2020) Yoshiaki Nakamura et al.   NATURE MEDICINE

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review

(2020) Sakti Chakrabarti et al.   Cancers

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid

(2019) Alexandra M. Miller et al.   NATURE

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).

(2019) Aparna Raj Parikh et al.   JOURNAL OF CLINICAL ONCOLOGY

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

(2019) Dominic G. Rothwell et al.   NATURE MEDICINE

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

(2019) Thomas Reinert et al.   JAMA Oncology

O-016Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer

(2019) A Parikh et al.   ANNALS OF ONCOLOGY

How liquid biopsies can change clinical practice in oncology

(2019) G Siravegna et al.   ANNALS OF ONCOLOGY

LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

(2019) J Taieb et al.   ANNALS OF ONCOLOGY

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

(2019) N Tarazona et al.   ANNALS OF ONCOLOGY

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

(2019) Jeanne Tie et al.   JAMA Oncology

Detection and localization of surgically resectable cancers with a multi-analyte blood test

(2018) Joshua D. Cohen et al.   SCIENCE

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

(2018) Jenny H. Lee et al.   JAMA Oncology

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.

(2018) Charles Swanton et al.   JOURNAL OF CLINICAL ONCOLOGY

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases

(2018) J Seoane et al.   ANNALS OF ONCOLOGY

Detection and surveillance of bladder cancer using urine tumor DNA

(2018) Jonathan C. Dudley et al.   Cancer Discovery

Integrating liquid biopsies into the management of cancer

(2017) Giulia Siravegna et al.   Nature Reviews Clinical Oncology

Integrated digital error suppression for improved detection of circulating tumor DNA

(2016) Aaron M Newman et al.   NATURE BIOTECHNOLOGY

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

Brain Tumor Mutations Detected in Cerebral Spinal Fluid

(2015) W. Pan et al.   CLINICAL CHEMISTRY

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas

(2015) Yuxuan Wang et al.   Science Translational Medicine

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

(2015) Leticia De Mattos-Arruda et al.   Nature Communications

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas

(2015) O. A. Zill et al.   Cancer Discovery

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

(2014) L. De Mattos-Arruda et al.   ANNALS OF ONCOLOGY

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

(2013) Leticia De Mattos-Arruda et al.   Nature Reviews Clinical Oncology

Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study

(2013) Valentina Casadio et al.   Biomed Research International